Key result
Tirzepatide cuts projected 5-year major cardiovascular events risk ~36% vs. insulin glargine in type 2 diabetes.
Why the study?
The study sought to compare the projected 5-year incidence of macrovascular and microvascular complications between tirzepatide, semaglutide, and insulin glargine in individuals with type 2 diabetes.
Does tirzepatide or semaglutide reduce the 5-year risk of macrovascular and microvascular complications in individuals with type 2 diabetes inadequately controlled by metformin compared to insulin glargine?
Does tirzepatide or semaglutide reduce the 5-year risk of macrovascular and microvascular complications in individuals with type 2 diabetes inadequately controlled by metformin compared to insulin glargine?
Microsimulation modeling suggests that tirzepatide and semaglutide may offer significant 5-year reductions in macrovascular and microvascular complications compared to insulin glargine in patients with type 2 diabetes.
Answers are grounded in this paper and cite their sources.
Projected MACE reduction with tirzepatide versus glargine should not yet alter practice; leaves open confirmation in dedicated long-term outcome trials.
AIM: This study compared the 5-year incidence rate of macrovascular and microvascular complications for tirzepatide, semaglutide and insulin glargine in individuals with type 2 diabetes, using the Building, Relating, Assessing, and Validating Outcomes (BRAVO) diabetes simulation model. RESEARCH DESIGN AND METHODS: This study was a 5-year SURPASS-2 trial extrapolation, with an insulin glargine arm added as an additional comparator. The 1-year treatment effects of tirzepatide (5, 10 or 15 mg), semaglutide (1 mg) and insulin glargine on glycated haemoglobin, systolic blood pressure, low-density lipoprotein and body weights were obtained from the SUSTAIN-4 and SURPASS-2 trials. We used the BRAVO model to predict 5-year complications for each study arm under two scenarios: the 1-year treatment effects persisted (optimistic) or diminished to none in 5 years (conservative). RESULTS: When compared with insulin glargine, we projected a 5-year risk reduction in cardiovascular adverse events [rate ratio (RR) 0.64, 95% confidence interval (CI) 0.61-0.67] and microvascular composite (RR 0.67, 95% CI 0.64-0.70) with 15 mg tirzepatide, and 5-year risk reduction in cardiovascular adverse events (RR 0.75, 95% CI 0.72-0.79) and microvascular composite (RR 0.79, 95% CI 0.76-0.82) with semaglutide (1 mg) under an optimistic scenario. Lower doses of tirzepatide also had similar, albeit smaller benefits. Treatment effects for tirzepatide and semaglutide were smaller but still significantly higher than insulin glargine under a conservative scenario. The 5-year risk reduction in diabetes-related complication events and mortality for the 15 mg tirzepatide compared with insulin glargine ranged from 49% to 10% under an optimistic scenario, which was reduced by 17%-33% when a conservative scenario was assumed. CONCLUSION: With the use of the BRAVO diabetes model, tirzepatide and semaglutide exhibited potential to reduce the risk of macrovascular and microvascular complications among individuals with type 2 diabetes, compared with insulin glargine in a 5-year window. Based on the current modelling assumptions, tirzepatide (15 mg) may potentially outperform semaglutide (1 mg). While the BRAVO model offered insights, the long-term cardiovascular benefit of tirzepatide should be further validated in a prospective clinical trial.
No takes yet. Share an insight, caveat, or question.
Niu et al. (2023) studied Type 2 diabetes inadequately controlled by metformin. Tirzepatide vs. Insulin glargine was evaluated on 5-year projected incidence of major adverse cardiovascular events (MACE) (RR 0.64, 95% CI 0.61-0.67). In a 5-year simulation model, tirzepatide reduced the projected risk of major adverse cardiovascular events by 36% compared with insulin glargine in individuals with type 2 diabetes.
Synapse has enriched 10 related papers. Consider them for comparative context: